MedTrace Logo

Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use

NCT02785406 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-12-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effectiveness of a medication called suvorexant in reducing anxiety, improving sleep, and reducing cocaine cravings or cocaine use.

Conditions

Interventions

DRUG

suvorexant

Subjects will receive suvorexant capsules (10 mg week 1, 20 mg week 2), once daily at 10 PM.

DRUG

Placebo (for suvorexant)

Subjects will receive placebo capsules once daily at 10 PM.

Sponsors & Collaborators

  • Peter McManus Charitable Trust

    collaborator OTHER

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Scott D. Lane, PhD · The University of Texas Health Science Center, Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2018-11-15
Completion
2018-11-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02785406 on ClinicalTrials.gov